Manmeet Soni - May 5, 2023 Form 4 Insider Report for REATA PHARMACEUTICALS INC (RETA)

Role
COO, CFO and President
Signature
/s/ Tracy Herson, attorney-in-fact
Stock symbol
RETA
Transactions as of
May 5, 2023
Transactions value $
$0
Form type
4
Date filed
5/9/2023, 04:35 PM
Previous filing
Mar 8, 2023
Next filing
May 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RETA Class A common stock Award $0 +50K +56.62% $0.00 138K May 5, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RETA Employee Stock Option (right-to-buy) Award $0 +50K $0.00 50K May 5, 2023 Class B common stock 50K $104.79 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On August 29, 2019, the reporting person was granted 50,000 Restricted Stock Units subject to performance criteria. On May 5, 2023, based on the satisfaction of certain performance criteria, the 50,000 RSUs vested.
F2 On August 29, 2019, the reporting person was granted an option to purchase 50,000 shares of Class B common stock subject to performance criteria. On May 5, 2023, based on the satisfaction of certain performance criteria, the option vested as to 50,000 shares.